Not Signed In -
Warts |
Plantar Warts |
Clinical Trial: Four Week Safety and Efficacy Study with a Topical Gel to Treat Common Warts in Pediatric Subjects
This study is currently recruiting patients.
|
Purpose
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
| Condition | Intervention | Phase |
|---|---|---|
| Warts | Drug: Resiquimod | Phase II |
MedlinePlus related topics: Warts
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title: A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Secondary Outcomes: Partial clearance of treated wart(s); Wart recurrence
Expected Total Enrollment: 84
Study start: March 2005; Expected completion: December 2006
Last follow-up: May 2006; Data entry closure: July 2006
Eligibility
Inclusion Criteria:
- Diagnosis of common warts
- Ages between 3 to 11
Exclusion Criteria:
Location and Contact Information
Missouri
Mercy Health Research, St. Louis, Missouri, 63141, United States; Recruiting
Leah McQuality, RN 314-251-8890 mcqulk@stlo.mercy.net
Elaine C. Siegfried, MD, Principal Investigator, Mercy Health Research
More Information
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 30, 2005
ClinicalTrials.gov Identifier: NCT00116675
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05
email this page
print this page
bookmark this page
feedback on this page
